Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomecompanyFelbamate 98%
Felbamate
Felbamate
Felbamate

Felbamate 98%

Price Get Latest Price
Packge 1MT1kg5kg10kg25kg
  • Min. Order:1MT
  • Time:2024-03-07

Product Details

  • Product NameFelbamate
  • CAS No.25451-15-4
  • EINECS No.247-001-4
  • MFC11H14N2O4
  • MW238.24
  • AppearanceSolidWhite
  • Melting point 148-1500C
  • storage temp. Keep in dark place,Inert atmosphere,Room temperature
  • Boiling point 511.9±50.0 °C(Predicted)
  • density 1.275±0.06 g/cm3(Predicted)

Company Profile Introduction

Apicore US LLC headquartered in New Jersey, USA, and its contract manufacturing organization, Apicore Pharmaceuticals Pvt Ltd (Gujarat, India) are dedicated to developing and manufacturing active pharmaceutical ingredients (APIs) at our facilities, located in Somerset, NJ and Gujarat, India for the worldwide pharmaceutical industry.   

Apicore LLC, a wholly owned subsidiary of RK Pharma Inc (www.rkpharmainc.com), is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products.

Our USFDA approved facilities in India (Visakhapatnam, Andhra Pradesh and Vadodara, Gujarat) are both equipped with state-of-the-art analytical and research capabilities.

While our worldwide network of locations seamlessly integrate with each other, each unit also independently houses a full suite of R&D, QA, QC, and Manufacturing Services. This facilitates a continuous real-time exchange of information, ideas, and data while eliminating redundancies and waste.

Recommended supplier

  • Since:2021-03-01
  • Address: Block no. 252-253, Opp. Jain Irrigation Co., Padra-Jambusar Highway, Tal. Padra,Village Dhobikuva, V
INQUIRY